Is Cdc25 a druggable target?

Lazo, JS and Wipf, P (2008) Is Cdc25 a druggable target? Anti-cancer agents in medicinal chemistry, 8 (8). 837 - 842.

Plain Text (licence) Available under License : See the attached license file. Download (1kB)

Abstract

Proper control of cell cycle progression requires the functionality of a small family of activating phosphatases termed Cdc25, which have been implicated in cancer and Alzheimer's disease. These protein tyrosine phosphatases are therefore recognized as attractive molecular targets for small molecules. We review the rationale, approaches, progress and challenges for developing small molecule inhibitors of the Cdc25 family. A number of potential chemical probes are discussed and their characteristics are summarized.

---

Share

Citation/Export:	Select format... Citation - Text Citation - HTML Endnote BibTex Dublin Core OpenURL MARC (ISO 2709) METS MODS EP3 XML Reference Manager Refer
Social Networking:	Share |

---

Details

Item Type:	Article
Status:	Published
Creators/Authors:	Creators Email Pitt Username ORCID Lazo, JS lazo@pitt.edu LAZO Wipf, P pwipf@pitt.edu PWIPF
Date:	1 January 2008
Date Type:	Publication
Journal or Publication Title:	Anti-cancer agents in medicinal chemistry
Volume:	8
Number:	8
Page Range:	837 - 842
DOI or Unique Handle:	10.2174/187152008786847738
Schools and Programs:	Dietrich School of Arts and Sciences > Chemistry
Refereed:	Yes
Article Type:	Review
MeSH Headings:	Animals; Cell Cycle; Enzyme Inhibitors--pharmacology; Humans; cdc25 Phosphatases--antagonists & inhibitors
Other ID:	NLM NIHMS123600, NLM PMC2752834
PubMed Central ID:	PMC2752834
PubMed ID:	19075566
Date Deposited:	23 Sep 2014 14:43
Last Modified:	19 Jul 2020 11:55
URI:	http://d-scholarship.pitt.edu/id/eprint/23059

---

Metrics

Monthly Views for the past 3 years

Plum Analytics

Altmetric.com

---

Actions (login required)

View Item